GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » United Therapeutics Corp (STU:UTH) » Definitions » Research & Development

United Therapeutics (STU:UTH) Research & Development : €396 Mil (TTM As of Mar. 2024)


View and export this data going back to . Start your Free Trial

What is United Therapeutics Research & Development?

Research & Development is the aggregate amount of research and development expenses during the year. United Therapeutics's Research & Development for the three months ended in Mar. 2024 was €96 Mil. Its Research & Development for the trailing twelve months (TTM) ended in Mar. 2024 was €396 Mil.

United Therapeutics Research & Development Historical Data

The historical data trend for United Therapeutics's Research & Development can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

United Therapeutics Research & Development Chart

United Therapeutics Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Research & Development
Get a 7-Day Free Trial Premium Member Only Premium Member Only 1,064.34 294.03 477.99 304.82 374.14

United Therapeutics Quarterly Data
Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
Research & Development Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 77.43 82.15 79.36 138.83 95.77

United Therapeutics Research & Development Calculation

This is the expense the company spent on research and development.

Research & Development for the trailing twelve months (TTM) ended in Mar. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was €396 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

United Therapeutics  (STU:UTH) Research & Development Explanation

If competitive advantage is created by a patent or tech advantage, at some point it will disappear.

High R&D usually dictates high SG&A which threatens the competitive advantage.

United Therapeutics Research & Development Related Terms

Thank you for viewing the detailed overview of United Therapeutics's Research & Development provided by GuruFocus.com. Please click on the following links to see related term pages.

United Therapeutics (STU:UTH) Business Description

Industry
GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » United Therapeutics Corp (STU:UTH) » Definitions » Research & Development
Comparable Companies
INCY TECH SRPT RPRX ROIV LEGN VKTX CERE ASND EXEL OCSE:NOVO B VRTX REGN ASX:CSL MRNA XKRX:207940 XKRX:068270 XBRU:UCB XBRU:ARGX BNTX
Traded in Other Exchanges
UTHR:USA
Address
1040 Spring Street, Silver Spring, MD, USA, 20910
Website
https://www.unither.com
United Therapeutics specializes in drug development for pulmonary arterial hypertension, a rare and progressive disease marked by abnormally high blood pressure in the arteries of the lungs. The company's therapies for PAH largely focus on the prostacyclin pathway, and many of its treatments are based on the same molecule, treprostinil. Most of the company's sales are generated within the United States. United Therapeutics also markets a pediatric oncology drug, but its focus largely remains in pulmonary arterial hypertension.

United Therapeutics (STU:UTH) Headlines

No Headlines